Stephanie R. Fink

TL;DR: A genomic classifier was developed and validated in a large patient cohort enriched with prostate cancer metastasis patients and a rising PSA that went on to experience metastatic disease and may be useful for identification of aggressive prostate cancer.

TL;DR: This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease.

TL;DR: Differences in incidence and anatomic site specificity of translocations between North American and non-North American cases may reflect geographic variability of infectious or other etiologic factors.

TL;DR: This is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment and response to platinum chemotherapy correlates with the source patient.

TL;DR: Treatment of GBM6 xenografts with PD0332991 significantly suppressed tumor cell proliferation and prolonged survival and supported the concept that GBM tumors lacking p16(INK4a) expression and with nonamplified CDK4 and wild-type RB status may be more susceptible to Cdk4/6 inhibition using PD033 192991.